Therapies targeting CPT1 exert anti-tumor effects, such as diminishing the formation of invadopodia in hepatocellular carcinoma cells [154] and abrogating the pro-tumor effects of TAMs in vivo and in vivo [85] (Table 2). This evidence concerns the gene CPT1A and neoplasm.